Lipoprotein Deficiency Syndromes 1986
DOI: 10.1007/978-1-4684-1262-8_20
|View full text |Cite
|
Sign up to set email alerts
|

Primary Lipoprotein Lipase Deficiency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
38
0
1

Year Published

1989
1989
2017
2017

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(39 citation statements)
references
References 33 publications
0
38
0
1
Order By: Relevance
“…Two half-sisters, IG and JG, were also studied and had approximately half the normal levels of HL activity. The HL-deficient subject (PG) had been taking ctofibrate since 1966 (which resulted in a drop of his TG from the 2000 to 4000 mg/dl range to less than 1000 mg/dl), 16 while IG and JG were not on lipid-lowering drugs or other medications that affect lipid metabolism.…”
Section: Study Subjectsmentioning
confidence: 99%
“…Two half-sisters, IG and JG, were also studied and had approximately half the normal levels of HL activity. The HL-deficient subject (PG) had been taking ctofibrate since 1966 (which resulted in a drop of his TG from the 2000 to 4000 mg/dl range to less than 1000 mg/dl), 16 while IG and JG were not on lipid-lowering drugs or other medications that affect lipid metabolism.…”
Section: Study Subjectsmentioning
confidence: 99%
“…One significant limitation in designing efficacy trials in familial LPLD is the limited number of patients available for participation. Familial LPLD is characterized as an ultra-orphan disease with a prevalence of only 1 per million (Brunzell, 1999). The investigators further limited participation in the trial in several ways including the requirement that subjects have substantial levels of circulating endogenous (but defective) LPL enzyme as a way to avoid transgene-specific B and T cell responses.…”
Section: Discussionmentioning
confidence: 99%
“…Familial lipoprotein lipase deficiency (LPLD) is a rare, autosomal recessive disorder affecting about 1 person per million (Brunzell, 1999). The underlying pathophysiology of LPLD is a lack of functionally active lipoprotein lipase (LPL), which plays an important role in triglyceride (TG), chylomicron (CM), and very low-density lipoprotein (VLDL) metabolism ( Fig.…”
Section: The Diseasementioning
confidence: 99%
“…It is one of several tissues that expresses LPL (EC 3.1.1.34), an enzyme that is involved in the clearance of circulating triglycerides by catalyzing the hydrolysis of the triglyceride core of circulating lipoproteins. Generalized transgenic (Tg) overexpression of LPL in mice results in a reduction of serum triglycerides and an increase in HDL cholesterol (9), whereas extreme hypertriglyceridemia has been observed in humans (10), cats (11,12), and mice (13) lacking LPL. The discordant regulation of LPL in skeletal muscle and adipose tissue serves to traffic circulating lipids toward oxidation or storage, depending upon the metabolic context (14).…”
mentioning
confidence: 99%